^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    T-lymphocyte cell therapy

    Related drugs:
    1year
    Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients (clinicaltrials.gov)
    P2, N=24, Recruiting, Ever Supreme Bio Technology Co., Ltd. | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2022 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    IDH wild-type • PD-1-L
    |
    ADCV01
    over1year
    Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2/3, N=26, Completed, AlloVir | Active, not recruiting --> Completed
    Trial completion
    |
    CD4 (CD4 Molecule) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    almost2years
    EMBOLD: Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis (clinicaltrials.gov)
    P1/2, N=134, Terminated, Atara Biotherapeutics | Trial completion date: Sep 2027 --> Jan 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2023 --> Nov 2023; Study was terminated as primary endpoint was not achieved
    Trial completion date • Trial termination • Trial primary completion date
    almost2years
    Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2/3, N=378, Terminated, AlloVir | Trial completion date: Dec 2024 --> Jan 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Jan 2024; Study discontinued as DSMB determined it was futile. No safety concerns were noted.
    Trial completion date • Trial termination • Trial primary completion date
    |
    HLA-B (Major Histocompatibility Complex, Class I, B)
    almost2years
    Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC) (clinicaltrials.gov)
    P3, N=97, Terminated, AlloVir | Trial completion date: Jun 2024 --> Jan 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Jan 2024; Study discontinued as DSMB determined it was futile. No safety concerns were noted.
    Trial completion date • Trial termination • Trial primary completion date
    almost2years
    Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P3, N=51, Terminated, AlloVir | N=80 --> 51 | Trial completion date: Jun 2024 --> Jan 2024 | Recruiting --> Terminated; Study discontinued as DSMB determined it was futile. No safety concerns were noted.
    Enrollment change • Trial completion date • Trial termination
    almost2years
    Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2/3, N=378, Active, not recruiting, AlloVir | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HLA-B (Major Histocompatibility Complex, Class I, B)
    2years
    Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B-Cell Lymphoma. (PubMed, Transplant Cell Ther)
    The ATTCK-20-03 trial serves as proof of principle regarding the ACTR approach that could potentially be used with other antibodies targeting other markers in other malignancies. Although the ACTR707 program has been discontinued, these results may support other programs in employing similar novel approaches of antibody-coupled T-cell activation.
    P1 data • Journal • Combination therapy • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • ACTR707
    over2years
    DELTA-1: ITIL-168 in Advanced Melanoma (clinicaltrials.gov)
    P2, N=29, Terminated, Instil Bio | N=130 --> 29 | Trial completion date: Aug 2028 --> Feb 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2024 --> Feb 2023; Business Decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • ITIL-168
    almost3years
    DELTA-2: ITIL-168 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=0, Withdrawn, Instil Bio | N=27 --> 0 | Trial completion date: Aug 2028 --> Dec 2022 | Active, not recruiting --> Withdrawn | Trial primary completion date: Feb 2024 --> Dec 2022
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • cyclophosphamide • ITIL-168
    almost3years
    Posoleucel Multivirus-Specific T Cell Therapy to Treat Disseminated Adenovirus Infection in a CAR-T Recipient (TCT-ASTCT-CIBMTR 2023)
    Case Background: In June 2022, a 69-year-old woman with relapsed/refractory MM (diagnosed in 2018) received LD chemotherapy containing fludarabine and cyclophosphamide given on Days 1 to 3 before a 2nd round of CAR-T therapy (her first dose was in April 2022)...Urine labs were consistent with acute kidney injury from acute tubular necrosis associated with her severe diarrhea and drug toxicity from cidofovir... The multivirus-specific T cell therapy posoleucel appeared to be safe and effective against refractory disseminated AdV infection in this elderly patient with immune insufficiency as the result of LD chemotherapy and CAR-T.
    Virus specific T cells
    |
    CD4 (CD4 Molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV
    almost3years
    Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=9, Suspended, NexImmune Inc. | Trial completion date: Nov 2022 --> Dec 2023 | Terminated --> Suspended | Trial primary completion date: Aug 2022 --> Nov 2023
    Trial completion date • Trial suspension • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    NEXI-002